Valneva (VALN) said Tuesday that, together with Instituto Butantan, it has launched a pilot vaccination program in Brazil using its chikungunya vaccine, Ixchiq.

The program, which will serve as the basis for post-marketing commitment studies, will be implemented in ten Brazilian municipalities as part of a partnership between Instituto Butantan and the Brazilian Ministry of Health, the company said.

The vaccine was granted marketing approval in Brazil for use in adults in April, the company said.